Search for stocks /

OneSource Specialty Pharma Limited Q2 FY26 Concall Decoded: – ₹3,758 cr revenue, yet management warns numbers may lie


1. Opening Hook

Just when the market was busy counting GLP-1 launch dates like astrologers predicting weddings, OneSource walked in and said, “Relax, we’re fully booked—but don’t trust our quarterly revenue.”
Yes, a listed company openly admitting that numbers may not reflect reality. Rare. Slightly alarming. Definitely interesting.

Canada delays, court drama, semaglutide suspense, and accounting gymnastics—all packed into one concall. Management sounded confident, busy, and slightly irritated that Wall Street still loves neat spreadsheets.

They’re manufacturing every day, sold out on capacity, expanding aggressively, and yet politely warning investors: “Please don’t judge us by Q3 or Q4.”

If that sounds contradictory, congratulations—you’re paying attention.
Read on. It gets spicier once capacity math, take-or-pay traps, and FY28 bravado enter the chat.


2. At a Glance

  • Revenue ₹3,758 cr (+12%) – Growth arrived, but not fast enough for impatient traders.
  • EBITDA ₹1,065 cr (+37%) – Margins flexed hard, accounting smiled back.
  • EBITDA Margin 28% (+506 bps) – Cost discipline finally remembered its job.
  • PAT ₹449 cr – From losses to profits; resurrection season confirmed.
  • Net Debt ₹9,033 cr – Capex binge ongoing, bankers still invited.
  • Working Capital ₹5,936 cr – Inventory bulking like a gym bro before summer.

3. Management’s Key Commentary

“As a CDMO, we are not dependent on regulatory approvals of our partners.”
(Translation: Delays are not our fault, please stop panicking 😏)

“We now have over 20 customers and nine launching outside Canada.”
(Translation: Canada drama won’t kill the party)

“We have stopped onboarding new DDC customers due to capacity constraints.”
(Translation: Demand > Supply, finally a good problem)

“We are reiterating ₹400 million base business and ₹500 million FY28 outlook.”
(Translation: Trust us till 2028, ignore the noise)

“Our numbers may not reflect the true nature of work we are doing.”
(Translation: Quarterly results are lying to you 😬)

“We had 37 successful inspections in H1.”
(Translation: Regulators love us, competitors hate us)

“No one globally offers device assembly across 10+ platforms like us.”
(Translation: Monopoly vibes, at least for now 😎)


4. Numbers Decoded

MetricQ2 FY26What It Really Means
Revenue₹3,758 crSteady, but not launch-led yet
EBITDA₹1,065 crOperating leverage waking up
EBITDA Margin28%CDMO sweet spot unlocked
PAT₹449 crLoss hangover finally cured
Net Debt₹9,033 crCapex now, cash later
Capacity (Pens)200+ mn unitsInstalled ≠ usable

Key takeaway: Capacity exists, monetization waits for approvals.


5. Analyst Questions (Decoded)

  • Canada risk?
    Management: “Multiple customers, multiple markets.”

Lalitha Diwakarla

Leave a Reply

Don't Miss

error: Content is protected !!